The amyotrophic lateral sclerosis-frontotemporal dementia (ALS-FTD) spectrum represents a clinicopathological continuum of neurodegenerative disorders characterized by overlapping clinical, genetic, and neuropathological features. ALS and FTD were historically considered distinct entities—ALS primarily affecting motor neurons causing progressive weakness, and FTD affecting frontal and temporal lobes causing cognitive and behavioral changes. However, recognition that these conditions share common genetic, pathological, and clinical features has led to the conceptualization of a unified disease spectrum 1. [1]
Approximately 15% of ALS patients meet criteria for FTD, while an additional 25-30% exhibit mild cognitive or behavioral changes falling short of full FTD diagnostic criteria. Conversely, up to 15% of FTD patients develop motor neuron disease features. This significant clinical overlap, combined with shared neuropathology (TDP-43 proteinopathy) and common genetic determinants (C9orf72 hexanucleotide repeat expansion), has established ALS-FTD as a single disease continuum 2. [2]
The spectrum encompasses several overlapping conditions: pure ALS, ALS with cognitive impairment, ALS-FTD, FTD with motor neuron features, and pure FTD. Patients may progress within this spectrum over time, with some presenting with ALS and later developing FTD features, or vice versa. Understanding this continuum has critical implications for diagnosis, clinical trial design, and therapeutic development 3. [3]
The most common genetic cause of familial ALS-FTD is an expanded hexanucleotide repeat in the first intron of the C9orf72 gene (chromosome 9p21). Normal individuals have fewer than 30 repeats, while pathogenic expansions contain hundreds to thousands of repeats. This mutation accounts for approximately 40% of familial ALS, 25% of familial FTD, and 5-10% of apparently sporadic cases 4. [4]
The pathogenic mechanisms include: [5]
Toxic RNA foci formation: The expanded repeat RNA forms nuclear foci that sequester RNA-binding proteins, including TDP-43 and splicing factors, disrupting normal RNA metabolism 5.
Dipeptide repeat (DPR) protein translation: Translation of the repeat in all reading frames generates five different dipeptide repeat proteins (poly-GA, poly-GR, poly-PR, poly-PA, poly-PR). These toxic proteins aggregate in neurons and disrupt various cellular processes including nucleocytoplasmic transport, autophagy, and stress granule dynamics 6.
Reduced C9orf72 expression: The expansion reduces transcription of the C9orf72 gene, leading to loss-of-function. C9orf72 protein is involved in endosomal trafficking and lysosomal function, and its reduction may contribute to neurodegeneration 7.
TARDBP encodes TDP-43, a nuclear RNA-binding protein that is the major component of the inclusions characteristic of ALS-FTD. Over 50 pathogenic mutations have been identified, predominantly in the C-terminal glycine-rich domain where they cause protein aggregation. TDP-43 pathology is present in approximately 95% of ALS cases and 50% of FTD cases 8. [6]
FUS encodes another RNA-binding protein involved in RNA splicing, transport, and translation. FUS mutations cause approximately 5% of familial ALS and are associated with aggressive early-onset disease. FUS-positive inclusions are a hallmark of a distinct subset of ALS-FTD cases 9. [7]
GRN (Progranulin): Loss-of-function mutations cause progranulin-deficient FTD (FTD-TDP type A), and some patients develop motor neuron features 10.
MAPT (Tau): Mutations in the microtubule-associated protein tau gene cause FTD-Tau, but motor neuron disease is uncommon 11.
ALSIN gene (ALS2): Juvenile-onset ALS with FTD features, caused by recessive ALSIN mutations 12.
SOD1 (Superoxide dismutase 1): First gene linked to familial ALS, but does not typically cause FTD 13.
The hallmark pathological feature of ALS-FTD is the presence of TDP-43 inclusions in neurons. TDP-43 is a normally nuclear protein that regulates RNA splicing, transcription, and transport. In disease, TDP-43 becomes hyperphosphorylated, ubiquitinated, and aggregates into cytoplasmic inclusions. These inclusions are found in motor neurons, cortical neurons, and various subcortical structures 14. [8]
Four morphological subtypes of FTLD-TDP have been described: [9]
Cases with C9orf72 expansions show unique pathological features: [10]
Dipeptide repeat proteins: Immunoreactive inclusions for poly-GA, poly-GR, poly-PR, and other DPRs, particularly in the frontal cortex and hippocampus 16.
Neuronal nucleolar stress: The C9orf72 repeat expansion causes nucleolar dysfunction, with TDP-43 translocating from nucleus to cytoplasm 17.
p62-positive inclusions: C9orf72 cases show p62-positive inclusions that are TDP-43 negative, representing DPR protein aggregates 18.
The classic ALS presentation involves progressive muscle weakness, typically beginning in the limbs (bulbar or limb onset) or respiratory muscles. Features include: [11]
FTD presentation involves changes in personality, behavior, or language: [12]
The diagnosis of ALS-FTD requires meeting criteria for both ALS and FTD: [13]
Longitudinal studies show that cognitive decline typically progresses faster than motor decline in ALS-FTD. Executive dysfunction is most common, followed by language and social cognition deficits. Memory and visuospatial functions are relatively preserved until later stages 22. [14]
The diagnostic workup for suspected ALS-FTD includes: [15]
Riluzole: The only FDA-approved disease-modifying therapy for ALS, providing modest survival benefit (2-3 months) 27.
Edaravone: Also FDA-approved for ALS, thought to reduce oxidative stress 28.
Bulbar management: Dysphagia evaluation, gastrostomy tube placement, speech therapy
Respiratory support: Non-invasive ventilation, cough-assist devices 29.
Spasticity management: Baclofen, tizanidine, botulinum toxin
Pseudobulbar affect: Dextromethorphan/quinidine 30.
Specialized ALS clinics provide coordinated care from neurologists, pulmonologists, gastroenterologists, physical and occupational therapists, speech therapists, social workers, and mental health professionals 32. [16]
Antisense oligonucleotides (ASOs): Targeting C9orf72 repeat RNA to reduce toxic RNA foci and DPR proteins. Clinical trials are underway 33.
Gene editing: CRISPR-Cas9 approaches to correct pathogenic mutations in preclinical models 34.
TDP-43 modulators: Small molecules to reduce TDP-43 aggregation or enhance its nuclear function 35.
Autophagy enhancers: Rapamycin and related compounds to promote clearance of protein aggregates 36.
Neuroinflammation reduction: Microglial modulators to reduce inflammatory-mediated neurodegeneration 37.
Multiple clinical trials target various aspects of ALS-FTD pathogenesis: [17]
The prognosis of ALS-FTD is generally worse than either pure ALS or pure FTD: [18]
Induced pluripotent stem cells (iPSCs): Patient-derived neurons show TDP-43 mislocalization, synaptic deficits, and altered stress responses 41.
Organoids: Brain organoids from ALS-FTD patients provide three-dimensional models of disease 42.
Additional evidence sources: [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34]
TDP-43 (TAR DNA-binding protein of 43 kDa) is encoded by the TARDBP gene on chromosome 1p36. This ubiquitously expressed protein is primarily nuclear and plays diverse roles in RNA metabolism:
RNA splicing: TDP-43 regulates alternative splicing of numerous pre-mRNAs, including its own transcript (autoregulation). It binds to UG-rich sequences in target RNAs and modulates splice site selection.
RNA transcription: TDP-43 interacts with transcription factors and the transcriptional machinery, influencing gene expression patterns.
RNA transport: Through association with transport proteins, TDP-43 facilitates RNA trafficking from nucleus to cytoplasm and within cytoplasmic compartments.
Stress granule formation: Under cellular stress, TDP-43 translocates to stress granules—cytoplasmic RNA-protein aggregates that temporarily stall translation to conserve resources.
In ALS-FTD, TDP-43 undergoes a pathological transformation:
Phosphorylation: At least 5 serine phosphorylation sites are targeted (S409, S410, S379, S403, S409/S410), creating pathological epitopes recognized by specific antibodies.
Ubiquitination: Pathological inclusions are ubiquitinated, marking them for degradation via the proteasome and autophagy pathways.
C-terminal fragmentation: Proteolytic cleavage generates C-terminal fragments (approximately 25-35 kDa) that are highly aggregation-prone and form the core of inclusions.
Mislocalization: The hallmark of TDP-43 pathology is cytoplasmic mislocalization—the protein exits the nucleus and accumulates in cytoplasmic inclusions.
Neuronal loss: The inclusions themselves may be toxic, and/or loss of nuclear TDP-43 function disrupts essential RNA processing.
Multiple mechanisms contribute to neurodegeneration:
RNA processing disruption: Loss of nuclear TDP-43 impairs splicing of critical neuronal RNAs, including those encoding synaptic proteins and mitochondrial function genes.
Stress granule persistence: Pathological TDP-43 localizes to stress granules but fails to dissociate properly, causing prolonged translational repression.
Mitochondrial dysfunction: TDP-43 inclusions impair mitochondrial transport and function, reducing neuronal energy supply.
Axonal transport defects: TDP-43 pathology disrupts the microtubule-based transport system essential for synaptic maintenance.
Nucleocytoplasmic transport impairment: In C9orf72 cases, DPR proteins and TDP-43 aggregates disrupt nuclear pore integrity.
The C9orf72 gene contains a GGGGCC hexanucleotide repeat in its first intron. This region is normally polymorphic:
The expansion arose from a common founder event (approximately 1500-2000 years ago), and all patients with the expansion share this ancestry.
The C9orf72 expansion causes neurodegeneration through three independent mechanisms:
1. Loss of Function (haploinsufficiency)
The expanded repeat causes reduced gene expression through:
C9orf72 protein is involved in:
Reduced C9orf72 impairs lysosomal function and autophagy, leading to accumulation of protein aggregates and damaged organelles.
2. RNA Toxicity (RNA Foci)
The expanded repeat RNA forms nuclear RNA foci that:
These foci are detected in patient brain tissue and model systems, and correlate with disease severity.
3. Dipeptide Repeat Protein Toxicity
Non-ATG translation of the repeat generates five DPR proteins:
These toxic proteins create a distinct pathology layer atop TDP-43.
ASOs are single-stranded DNA oligonucleotides that:
For C9orf72:
Multiple clinical trials have tested C9orf72-targeting ASOs, with mixed results. Challenges include:
The most common overlapping presentation combines behavioral disinhibition with motor neuron disease:
Behavioral features:
Motor features:
This subtype carries the worst prognosis, with survival often under 2 years from symptom onset.
Characterized by progressive loss of word meaning and object knowledge combined with motor features:
Language features:
Motor features:
This subtype has slightly better survival than bvFTD-ALS.
A lower motor neuron-predominant syndrome that may evolve into ALS and FTD:
An upper motor neuron syndrome that may overlap with FTD:
Definite ALS: Clinical evidence of UMN and LMN signs in three regions
Probable ALS: Clinical evidence of UMN and LMN signs in two regions, with UMN signs rostral to LMN signs
Possible ALS: Clinical evidence of UMN and LMN signs in one region, or UMN signs alone in two regions
Laboratory-supported probable ALS: EMG evidence of LMN signs in two regions with normal neuroimaging
Behavioral Variant FTD (Rascovsky criteria):
Primary Progressive Aphasia Variants:
Strong ALS-FTD: Both ALS and FTD criteria met at initial evaluation
Weak ALS-FTD: ALS criteria met, then FTD features develop, or vice versa
ALS with cognitive impairment: ALS with cognitive changes not meeting FTD criteria
ALS with behavioral impairment: ALS with behavioral changes not meeting FTD criteria
Assessment:
Interventions:
Monitoring:
Interventions:
Muscle cramps:
Spasticity:
Pseudobulbar affect:
Pain:
Salivation:
Disease-modifying therapies:
Off-label options studied:
Advance care planning is essential:
Neurofilament chains:
TDP-43 species:
Genetic biomarkers:
Structural MRI:
Functional imaging:
Diffusion imaging:
Nucleocytoplasmic transport modulators:
Stress granule inhibitors:
Autophagy modulators:
Anti-TDP-43 antibodies:
Anti-inflammatory strategies:
Stem cell approaches:
Gene therapy vectors:
ALS-FTD places extraordinary demands on caregivers:
Support interventions:
For families with C9orf72 or other ALS-FTD mutations:
Testing considerations:
Reproductive options:
Insurance considerations:
Legal planning:
MAPT mutations in FTD (2017). 2017. ↩︎
ALS2 and juvenile ALS (2017). 2017. ↩︎
SOD1 mutations (2018). 2018. ↩︎
FTLD-TDP subtypes (2017). 2017. ↩︎
C9orf72 DPR pathology (2014). 2014. ↩︎
ALS clinical features (2018). 2018. ↩︎
FTD clinical features (2017). 2017. ↩︎
[ALS-FTD diagnostic criteria (2018)](https://doi.org/10.1016/S1474-4422(18). 2018. ↩︎
Neuroimaging in ALS-FTD (2017). 2017. ↩︎
Neurophysiology in ALS (2018). 2018. ↩︎
Riluzole in ALS (2014). 2014. ↩︎
Edaravone in ALS (2017). 2017. ↩︎
Management of ALS (2018). 2018. ↩︎
C9orf72 ASO trials (2020). 2020. ↩︎
Gene editing approaches (2021). 2021. ↩︎
TDP-43 modulators (2018). 2018. ↩︎
Autophagy enhancement (2017). 2017. ↩︎
Prognosis in ALS-FTD (2017). 2017. ↩︎
Mouse models of ALS-FTD (2015). 2015. ↩︎
iPSC models of ALS-FTD (2017). 2017. ↩︎
Brain organoids (2018). 2018. ↩︎
Epidemiology of ALS-FTD (2017). 2017. ↩︎